Appendix A

MONITORING THE PROGRAMME, TABULATION OF PARAMETERS

*Table 1. Coverage within a 3-year screening round**

Age	Women with at least one smear	Mid-population	Per cent
<15			
15–19			
20–24			
25–29			
30–34			
35–39			
40–44			
45–49			
50–54			
55–59			
60–64			
65–69			
70–74			
75+			
			Total, women

*Or 5-year screening round depending on local organisation

Table 2. Interval to reporting

	Age of women			
Interval	<25	25–64	≥65	Total
0–7 days				
8–14 days				
15–21 days				
>3 weeks				
Total, smears				

Table 3. Proportion of unsatisfactory smears

Smear result	Age of women <25	25–64	≥65	Total
1. Invasive cancer				
2. CIN3				
3. GIN3				
4. CIN2				
5. CIN1 (including koilocytotic atypia)				
6. Other intraepithelial neoplastic lesion				
7. Abnormal (not neoplasia)				
8. Other abnormal changes				
9. Satisfactory				
10. Unsatisfactory				
Total, smears				
10/total				

Table 4. Follow-up compliance for abnormal smears

Follow-up interval in months	Age of women <25	25–64	≥65	Total
<3				
3–6				
7–12				
>12				
No follow-up				
Total, abnormal smears				

This table should also be made available for each type of abnormal smear.

Table 5. Follow-up compliance for women with at least one abnormal smear

	Age of women			
Follow-up interval in months	<25	25–64	≥65	Total
<3				
3–6				
7–12				
>12				
No follow-up				
Total, women with abnormal smear				

Table 6. Treatment compliance 1. Number of women by most severe diagnosis within a given screening round

	Age of women			
Most severe diagnosis	<25	25–64	≥65	Total
Histologically verified				
CCU, Adenocarcinoma				
CCU, Squamous cell				
CCU, NOS				
CCU, clinical only				
Cancer of other site				
Carcinoma *in situ* CIN3				
Adenocarcinoma *in situ* GIN3				
Severe dysplasia CIN3				
Moderate dysplasia CIN2				
Mild dysplasia CIN1 (including koilocytotic atypia)				
Mixed lesions				
Dysplasia NOS				
Positive				
Abnormal (not neoplasia)				
Normal				
Unsatisfactory				
Not-classifiable				
Cytologically verified only				
Invasive				
CIN3				
GIN3				
CIN2				
CIN1 (including koilocytotic atypia)				
Other intraepithelial neoplastic lesions				
Abnormal (not neoplasia)				
Other abnormal changes				
Satisfactory				
Unsatisfactory				
No histology or cytology				
Total, women				

NOS = not otherwise specified. CCU = cancer of the cervix uteri.

Table 7. Treatment compliance 2. Number of women by most radical treatment for given diagnosis

Most radical treatment	Age of women <25	25–64	≥65	Total
Radiotherapy/chemotherapy				
Radical hysterectomy				
Total hysterectomy				
Amputation of cervix				
Conisation				
Local destructive treatment				
Other relevant procedure				
No treatment				
Total, women with given diagnosis				

This table will be made for each group of women defined by most severe diagnosis.

Table 8. Smear sensitivity for detection of invasive cervical cancer

Most severe smear in last year	Age of women <25	25–64	≥65	Total
1. Invasive				
2. CIN3				
3. GIN3				
4. CIN2				
5. CIN1 (including koilocytotic atypia)				
6. Other intraepithelial neoplastic lesions				
7. Abnormal (not neoplasia)				
8. Other abnormal changes				
9. Satisfactory				
10. Unsatisfactory				
Total, invasive cervical cancers 1–7/1–10				

This table includes incident cases of invasive cervical cancer diagnosed during the first year after completion of a screening round.

Table 9. Distribution of incident cases. Invasive cervical cancer cases by stage

	Age of women			
	<25	25–64	≥65	Total
CCU, adenocarcinoma				
Stage 1a				
Stage 1b				
Stage 2				
Stage 3				
Stage 4				
CCU, squamous cell				
Stage 1a				
Stage 1b				
Stage 2				
Stage 3				
Stage 4				
CCU, NOS				
Stage 1a				
Stage 1b				
Stage 2				
Stage 3				
Stage 4				
CCU, Clinical only				
Stage 1a				
Stage 1b				
Stage 2				
Stage 3				
Stage 4				
Total				
Stage 1a				
Stage 1b				
Stage 2				
Stage 3				
Stage 4				

Table 10. Distribution of incident cases. Invasive cervical cancer cases by detection

	Age of women			
	<25	25–64	≥65	Total
CCU, adenocarcinoma				
Screen detected				
Interval				
Non-screened				
CCU, squamous cell				
Screen detected				
Interval				
Non-screened				
CCU, NOS				
Screen detected				
Interval				
Non-screened				
CCU, clinical only				
Screen detected				
Interval				
Non-screened				
Total				
Screen detected				
Interval				
Non-screened				

Table 11. *Interval cancers. Incidence of invasive cervical cancer by time since last normal smears*

Years since last normal smear	Age of women <25	25–64	≥65	Total
Incident cancer cases				
0–1				
1–2				
2–3*				
Person years at risk				
0–1				
1–2				
2–3				
Observed incidence				
0–1				
1–2				
2–3				

This table includes women for whom the first smear in a given screening round is normal. Person years at risk are accumulated from date of the normal smear until next smear, next biopsy or exit from the area.
*Followed by 3–4, 4–5 years if local screening round is longer than 3 years.

Table 12. *Interval cancers re-evaluation of previous smears*

Original evaluation Most severe smear diagnosis	Re-evaluation, most severe diagnosis: Within 1 year from diagnosis smear diagnosis	Within 2 years from diagnosis smear diagnosis	Within 3 years from diagnosis smear diagnosis
Within 1 year from diagnosis Smear diagnosis			
●			
●			
●			
Within 2 years from diagnosis Smear diagnosis			
●			
●			
●			
Within 3 years from diagnosis Smear diagnosis			
●			
●			
●			

Table 13. *Consumption of smears*

Age	Numbers of smears used	Mid population	Smears per woman
<15			
15–19			
20–24			
25–29			
30–34			
35–39			
40–44			
45–49			
50–54			
55–59			
60–64			
65–69			
70–74			
75+			
Total	Smears	Women	Smears/woman

Table 14. *Distribution of smears, per cent of women with more than one smear*

Age	Women with at least two smears	Mid population	Per cent
<15			
15–19			
20–24			
25–29			
30–34			
35–39			
40–44			
45–49			
50–54			
55–59			
60–64			
65–69			
70–74			
75+			
Total women			

Table 15. *Distribution of smears, per cent of women with abnormal smear*

Age	Women with at least one abnormal smear	Mid population	Per cent
<15			
15–19			
20–24			
25–29			
30–34			
35–39			
40–44			
45–49			
50–54			
55–59			
60–64			
65–69			
70–74			
75+			
Total women			

Note: This table should be made also for women with an unsatisfactory smear.

Table 16. *Use of smears in a screening round*

	Number of smears	Per cent of total
1. Smears for women below age 25		
2. First smears for women aged 25–64		
3. Follow-up smears (e.g. two additional smears for each atypical), for women aged 25–64		
4. All other smears for women aged 25–64		
5. Smears for women aged 65 and above		
Total, smears 2+3/1+2+3+4+5		

Table 17. *Incidence of invasive cervical cancer before and after start of organised screening programme*

	Time period			First 3-year screening round, e.g.		
Age	1984–1986	1987–1989	1990–1992	1993–1995*	1996–1998	1999–2001
<15						
15–19						
20–24						
25–29						
30–34						
35–39						
40–44						
45–49						
50–54						
55–59						
60–64						
65–69						
70–74						
75+						
Total						

This table should be made for: cases; population; incidence rates. For: screening area; comparison regions.
*Or 5-year screening round, depending on local programme.

Table 18. *Mortality from cervical cancer before and after start of organised screening programme*

	Time period			First 3-year screening round e.g.		
Age	1984–1986	1987–1989	1990–1992	1993–1995*	1996–1998	1999–2001
<15						
15–19						
20–24						
25–29						
30–34						
35–39						
40–44						
45–49						
50–54						
55–59						
60–64						
65–69						
70–74						
75+						
Total						

This table should be made for: deaths; population; mortality rates. For: catchment area; comparison regions.
*Or 5-year screening round, depending on local programme.